The humoral response to Pfizer / BioNTech BNT162b2 vaccine is altered in patients receiving CAR-T or high intensity immunosuppressive therapy
THE HAGUE, Netherlands, June 12, 2021 / PRNewswire / – Pfizer / BioNTech BNT162b2 vaccine has been approved for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is recommended for immunocompromised patients. However, its efficacy and safety in patients on immunological cell therapy has not been well documented. In this study, we evaluated the efficacy and safety of BNT162b2 vaccine in patients who underwent hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) -T therapy. We prospectively followed 79 vaccinated patients who were actively treated at Tel Aviv Sourasky Medical Center and monitored the safety profile and humoral immune response to the vaccine.
Overall, the vaccine was well tolerated and all adverse events resolved within days, with the exception of secondary transplant rejection, which is still under investigation. We observed that only 36% of patients who received CAR-T therapy developed a humoral antibody response, compared to 81% of patients who underwent allogeneic HCT. In addition, patients with B-cell aplasia and those who received the vaccine soon after the cell infusion were less likely to develop antibodies. Taken together, these data demonstrate that the humoral response to BNT162b2 vaccine is significantly altered in patients receiving CAR-T, as opposed to those after allogeneic HCT who had a good response.
Presenter: Professor Ron ram
Affiliation: BMT Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Abstract: # S285 SAFETY AND EFFECTIVENESS OF COVID-19 MRNA BNT162B2 VACCINE IN PATIENTS AFTER CD19-BASED HCT AND CAR-T ALLOGENIC THERAPY – A SINGLE-CENTER PROSPECTIVE COHORT STUDY
About the EHA Annual Congress: Every June, the EHA holds its annual congress in a major European city. This year, due to the persistence of the COVID19 pandemic, the EHA is organizing a virtual congress for the second time. The Congress is aimed at health professionals working or interested in the field of hematology. The subjects of the scientific program range from physiology and development of stem cells to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and coagulation disorders; as well as transfusion and transplantation of stem cells.
SOURCE European Hematology Association (EHA)